Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;38(1):316-328.
doi: 10.1007/s12325-020-01540-6. Epub 2020 Oct 28.

A Global Survey of Disease Burden in Patients Who Carry a Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy

Jeffrey A Allen  1 , Lisa Butler  2 , Todd Levine  3 , Anne Haudrich  4
Affiliations

A Global Survey of Disease Burden in Patients Who Carry a Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy

Jeffrey A Allen et al. Adv Ther. 2021 Jan.

Erratum in

Abstract

Introduction: The extent to which work productivity, emotional well-being, social interactions, and family life are impacted in patients who self-identify as having chronic inflammatory demyelinating polyneuropathy (CIDP) is not well characterized.

Methods: Data from an online survey of 595 individuals with self-reported CIDP, recruited by the Guillain-Barré syndrome (GBS)/CIDP Foundation, were used to assess disease and treatment burden. A total of 37% of patients were classified as "likely", 34% as "somewhat likely", and 28% as "unlikely" CIDP.

Results: Of ten symptoms that patients with CIDP may experience, each symptom was experienced by 77-94% of "likely", 79-96% of "somewhat likely", and 66-91% of "unlikely" patients. In "likely" CIDP patients 44% stopped working because of their symptoms and 24% moved to a new home. The most common treatments were intravenous immunoglobulin (IVIg) infusion and corticosteroids. IVIg was associated with venous access issues and work/school absenteeism.

Conclusions: CIDP diagnostic confirmation was not performed in any of the survey respondents. Our results do not add any knowledge on the diagnosis or treatment of CIDP. Our findings do provide insight into the symptoms that patients that think they have CIDP or have been told they have CIDP experience, explores how patients that are labeled as having CIDP view treatment expectations, and highlights how these symptoms affect home and work life. We hope that the findings are constructively used to get patients the services they need to improve quality of life, maintain employment, and ensure a safe home environment regardless of diagnostic accuracy.

Keywords: CIDP; Disease burden; Supportive care.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Symptoms ever experienced (a) and number of symptoms ever experienced (b)
Fig. 2
Fig. 2
Most bothersome symptoms when treatment started (a) and symptoms they most wanted relief from currently (b). Respondents were allowed to select up to three most bothersome symptoms
Fig. 3
Fig. 3
Survey responses of “always” or “often”* on feelings about their future. *Respondent options: Never, Rarely, Sometimes, Often, Always. N=593 for questions ‘I won’t be able to afford my CIDP treatment’ and ‘Concerned that costs of treatment will lead to other financial struggles’, all other questions N=595
Fig. 4
Fig. 4
Changes made to work (a) and home (b) as a result of symptoms that have been attributed to CIDP
Fig. 5
Fig. 5
Primary reason for discontinuing treatment of IVIg (a) and corticosteroids (b)
Fig. 6
Fig. 6
Percentage of patients who missed work/school in the past month because of IVIg infusions by amount of time missed
See this image and copyright information in PMC

References

    1. Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011;7(9):507–517. doi: 10.1038/nrneurol.2011.121. - DOI - PubMed
    1. Mathey EK, Park SB, Hughes RA, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86(9):973–985. doi: 10.1136/jnnp-2014-309697. - DOI - PMC - PubMed
    1. Chio A, Cocito D, Bottacchi E, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry. 2007;78(12):1349–1353. doi: 10.1136/jnnp.2007.114868. - DOI - PMC - PubMed
    1. Gorson KC, van Schaik IN, Merkies IS, et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst. 2010;15(4):326–333. doi: 10.1111/j.1529-8027.2010.00284.x. - DOI - PubMed
    1. Cocito D, Paolasso I, Antonini G, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2010;17(2):289–294. doi: 10.1111/j.1468-1331.2009.02802.x. - DOI - PubMed

Publication types

MeSH terms